APAC Cancer Vaccines Market Report

APAC Cancer Vaccines Market Size

The Asia-Pacific Cancer Vaccines Market is projected to grow from USD 1.03 billion in 2025 to USD 1.22 billion in 2026 and reach USD 4.65 billion by 2034, registering a CAGR of 18.24% during the forecast period from 2026 to 2034.

MARKET DRIVERS

Rising Prevalence of Preventable Cancers Linked to Viral Infections

One of the primary drivers of the APAC Cancer Vaccines Market is the rising prevalence of preventable cancers associated with viral infections , particularly Human Papillomavirus (HPV), Hepatitis B Virus (HBV), and Epstein-Barr Virus (EBV).

According to the World Health Organization (WHO), over 30% of all cancer cases in the APAC region are attributable to infectious agents , making vaccines a crucial tool in cancer prevention.

In China , the Chinese Center for Disease Control and Prevention reports that liver cancer remains the second most common cause of cancer-related deaths , largely driven by chronic HBV infection. To address this, the Chinese government has expanded infant HBV immunization programs, which have been shown to reduce liver cancer incidence in vaccinated populations .

Similarly, India faces a high burden of cervical cancer , with the Indian Council of Medical Research (ICMR) noting that it accounts for nearly 22% of global cervical cancer deaths . Recognizing this, several Indian states have initiated pilot HPV vaccination campaigns, signaling a shift toward vaccine-driven cancer prevention strategies.

Moreover, Japan and South Korea have integrated HPV vaccines into their national immunization schedules , contributing to declining cervical cancer rates. As more governments in the region recognize the cost-effectiveness of prophylactic vaccines, demand for cancer vaccines is expected to surge, reinforcing their role in public health planning.

Government Support and Public Health Initiatives

Another significant driver of the APAC Cancer Vaccines Market is increased government backing and public health initiatives aimed at expanding access to cancer-preventive vaccines. Across the Asia-Pacific region, policymakers are increasingly recognizing the long-term economic and health benefits of immunization programs targeting virus-associated cancers.

In Australia , the National HPV Vaccination Program has achieved over 85% coverage among adolescent girls and boys , contributing to a decline in HPV infection rates since its launch , as reported by the Australian Institute of Health and Welfare . This success has positioned Australia as a regional leader in vaccine-based cancer prevention.

In Malaysia , the Ministry of Health launched a nationwide HPV vaccination drive in 2023, aiming to cover over 100,000 students annually. The initiative was backed by a multi-million-dollar allocation in the national budget, reflecting the country's commitment to reducing cervical cancer incidence.

Similarly, Thailand has introduced free HPV vaccinations in schools , aligning with WHO recommendations for comprehensive cancer control strategies.

These policy-level interventions not only increase vaccine accessibility but also foster public trust and awareness. With governments across the APAC region allocating increased funding for immunization campaigns , the cancer vaccines market is poised for sustained growth, driven by strong institutional support and strategic healthcare planning.

MARKET RESTRAINTS

High Development and Deployment Costs

A major restraint affecting the APAC Cancer Vaccines Market is the high cost associated with vaccine development, clinical trials, and large-scale deployment , which limits accessibility in low- and middle-income countries.

In Southeast Asia , many national health systems struggle to integrate expensive vaccines into routine immunization programs. For example, the Philippine Department of Health noted that the cost of HPV vaccines remains a barrier to universal coverage , especially in rural areas where public health budgets are constrained.

Also, therapeutic cancer vaccines , which are still in early stages of commercialization, face even higher costs due to personalized manufacturing and complex bioprocessing requirements.

This economic challenge is compounded by limited reimbursement policies in many APAC countries, discouraging pharmaceutical companies from entering price-sensitive markets. Without robust funding mechanisms and international partnerships, the widespread adoption of cancer vaccines will remain hindered, particularly in lower-resource settings.

Limited Awareness and Vaccine Hesitancy

Another key constraint on the APAC Cancer Vaccines Market is low public awareness and persistent vaccine hesitancy , particularly in rural and conservative communities. Despite growing scientific consensus on the efficacy of cancer vaccines, misinformation and cultural skepticism continue to impede uptake , especially for HPV and HBV vaccines.

In Indonesia , for instance, HPV vaccine acceptance dropped to 45% in certain provinces due to concerns raised by religious and community leaders regarding perceived safety issues and ethical implications. This has delayed nationwide rollout plans and weakened herd immunity against cervical cancer.

Similarly, in Papua New Guinea , a lack of education around vaccine-preventable diseases has resulted in one of the lowest immunization rates in the region , according to the United Nations Children's Fund (UNICEF) . Low literacy levels and limited access to health information contribute to poor vaccine penetration in remote areas.

Addressing these knowledge gaps requires sustained investment in community engagement, healthcare worker training, and culturally sensitive communication strategies. Until public perception shifts and confidence in vaccine safety improves, vaccine hesitancy will remain a critical obstacle to market growth in the APAC region .

MARKET OPPORTUNITIES

Expansion of Therapeutic Cancer Vaccine Development

One of the most promising opportunities in the APAC Cancer Vaccines Market is the rapid advancement of therapeutic cancer vaccines , which are being developed to treat existing malignancies rather than prevent them. Unlike traditional vaccines, these immunotherapeutic products are tailored to stimulate the immune system to target specific tumor antigens, offering a novel approach to cancer treatment.

In South Korea , companies like GC Pharma and Genexine are investing heavily in therapeutic vaccine research, with several candidates currently in Phase II and III clinical trials. As per the Korean Biomedical Review, the country’s regulatory framework is becoming more supportive of personalized medicine, accelerating the approval process for innovative cancer vaccines.

In Japan , the Ministry of Health, Labour and Welfare has fast-tracked several dendritic cell-based vaccines for melanoma and prostate cancer, encouraging domestic biotech firms to expand their pipelines.

In Australia, the Garvan Institute of Medical Research is conducting trials on neoantigen-targeted vaccines, which hold promise for treating solid tumors. With growing investment in biotechnology hubs across the APAC region, therapeutic cancer vaccines represent a high-growth segment with substantial potential to transform oncology care delivery.

Growth of Biotech Innovation and Regional Manufacturing Hubs

The APAC region is witnessing a surge in biotech innovation , presenting a major opportunity for the Cancer Vaccines Market . Countries such as Singapore, South Korea, and India are establishing themselves as biopharmaceutical manufacturing powerhouses, attracting both domestic and international investment in vaccine development.

Meanwhile, Australia’s Cooperative Research Centre for Cancer Immunotherapy (CRI) is fostering cross-border partnerships with Japanese and South Korean firms to develop targeted vaccine therapies for melanoma and ovarian cancer. These developments indicate that the APAC Cancer Vaccines Market is well-positioned for accelerated growth through localized innovation and strategic manufacturing alliances .

MARKET CHALLENGES

Regulatory Complexity and Approval Delays

A major challenge facing the APAC Cancer Vaccines Market is the complex and inconsistent regulatory environment across different countries , which delays product approvals and hampers market entry. While some nations like Japan and Australia have well-established regulatory frameworks, others, including Indonesia and the Philippines , face prolonged review timelines and unclear guidelines for biologics and vaccines.

Such delays hinder timely access to life-saving vaccines and discourage multinational pharmaceutical companies from entering smaller markets.

In India , the Central Drugs Standard Control Organization (CDSCO) has faced criticism for lengthy clinical trial approvals , particularly for novel therapeutic vaccines. As per a report by Pharmexcil , the Indian pharmaceutical export promotion council, approval delays have discouraged over 40% of biotech firms from pursuing domestic vaccine development. Furthermore, differences in regulatory standards between ASEAN nations create compliance challenges for manufacturers seeking multi-country distribution . These complexities delay market expansion and limit equitable access to cancer vaccines across the APAC region.

Supply Chain and Distribution Limitations in Rural Areas

Another pressing challenge in the APAC Cancer Vaccines Market is the inadequate supply chain infrastructure , particularly in rural and remote areas , which restricts vaccine availability and administration. Many cancer vaccines require cold-chain logistics, making transportation and storage difficult in regions with unreliable electricity and healthcare infrastructure.

In Bangladesh, according to the Directorate General of Health Services, only 30% of rural clinics have functional cold chain facilities , limiting HPV vaccine coverage outside major cities. Similarly, in Papua New Guinea , transportation barriers and poor road networks result in significant vaccine wastage and low immunization rates .

To address this, organizations like Gavi, the Vaccine Alliance , have partnered with local governments to deploy solar-powered refrigerators and mobile immunization units. However, scaling these solutions remains financially and logistically challenging . Without significant investment in cold chain infrastructure and last-mile distribution networks , the APAC Cancer Vaccines Market will continue to face bottlenecks in reaching underserved populations .

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Cancer Type Insights

The cervical cancer vaccines segment dominated the APAC Cancer Vaccines Market, accounting for approximately 38% of total market revenue in 2025. This is primarily attributed to the high disease burden associated with Human Papillomavirus (HPV), which is a leading cause of cervical cancer across the region.

In India, cervical cancer remains a major public health concern. To address this, several Indian states have initiated pilot HPV vaccination campaigns, signaling a shift toward vaccine-driven cancer prevention strategies.

Similarly, China faces a significant cervical cancer burden, with over 100,000 new cases reported annually, according to the National Cancer Center of China. The government has been expanding HPV vaccine access through public-private partnerships and increasing awareness about early immunization.

Additionally, Japan and South Korea have integrated HPV vaccines into their national immunization schedules, contributing to declining cervical cancer rates. As more governments in the region recognize the cost-effectiveness of prophylactic vaccines, demand for cervical cancer vaccines is expected to surge, reinforcing their role in public health planning.

The prostate cancer vaccines segment is projected to grow at the fastest CAGR of 14.6%. This rapid growth is primarily driven by rising prostate cancer incidence and growing investment in personalized immunotherapies tailored to male populations in the APAC region.

In Australia, the Australian Institute of Health and Welfare reports that prostate cancer is the most commonly diagnosed cancer among men, with over 25,000 new cases recorded annually. This has prompted increased funding for therapeutic vaccines targeting prostate-specific antigens (PSA) and other tumor markers.

In Japan, the Ministry of Health, Labour and Welfare has fast-tracked several dendritic cell-based vaccines for prostate cancer, encouraging domestic biotech firms to expand their pipelines. According to the Japanese Society of Clinical Oncology , clinical trials have demonstrated improved survival outcomes in metastatic prostate cancer patients receiving vaccine-based immunotherapy.

Moreover, South Korea’s National Cancer Center notes that incidence rates for prostate cancer have doubled over the past decade, largely due to aging demographics and lifestyle changes.

By Vaccine Type Insights

The protein-based cancer vaccines segment held the largest share of the APAC Cancer Vaccines Market, capturing 32.5% of total revenue in 2025. These vaccines are widely used in preventive applications, particularly for virus-associated cancers such as cervical and liver cancer.

One key driver behind this segment's dominance is the widespread use of recombinant protein technology in HPV and HBV vaccines , which offer strong immunogenicity without requiring live viral components. According to the World Health Organization (WHO) , over 85 million doses of recombinant HPV vaccines were distributed across APAC countries in 2023 , significantly boosting market penetration.

In Australia , the National HPV Vaccination Program relies heavily on protein-based vaccines, achieving over 85% coverage among adolescent girls and boys , as noted by the Australian Institute of Health and Welfare. This success has positioned Australia as a regional leader in vaccine-based cancer prevention.

In China , the Chinese Center for Disease Control and Prevention highlights that protein-based HBV vaccines have contributed to an 80% decline in chronic hepatitis B infection among vaccinated children , reducing long-term liver cancer risk. With continued adoption across public health systems, protein-based vaccines remain the cornerstone of APAC cancer immunization programs.

The genetic cancer vaccines segment is anticipated to grow at the highest CAGR of 16.2% during the forecast period. This rapid expansion is driven by advancements in mRNA and DNA vaccine technologies, particularly in response to the post-pandemic acceleration of genetic vaccine platforms.

In Japan , the Ministry of Health, Labour and Welfare has supported clinical trials for mRNA-based neoantigen vaccines targeting melanoma and pancreatic cancer , with promising preliminary results. As per the University of Tokyo’s Department of Immunology , these vaccines offer high specificity and can be rapidly developed against individual tumor profiles.

In South Korea , companies like GeneOne Life Science and EuBiologics are developing DNA-based cancer vaccines with support from the Korean Biomedical Review, noting that these vaccines can be manufactured quickly and tailored to patient-specific mutations.

Besides, Australia’s Garvan Institute of Medical Research is conducting trials on personalized mRNA cancer vaccines , aligning with global trends in precision oncology.

COUNTRY LEVEL ANALYSIS

China remained the largest contributor to the APAC Cancer Vaccines Market, holding 24.4% of total regional revenue in 2025. Positioned as a strategic player in both preventive and therapeutic vaccine development, China benefits from a large population base, rising cancer incidence, and robust government-backed immunization programs.

Apart from these, China’s biopharma sector is experiencing rapid innovation. Companies like CanSino Biologics and Sinovac are expanding their portfolios beyond infectious diseases to include oncology vaccines. With increasing private healthcare spending and supportive regulatory reforms , China continues to lead the APAC Cancer Vaccines Market, setting the stage for sustained growth in both preventive and therapeutic segments.

India is a significant player in the APAC Cancer Vaccines Market , driven largely by its massive unmet medical need and recent policy shifts toward national immunization programs, according to Statista. The country bears a disproportionately high cervical cancer burden, making HPV vaccination a critical public health priority.

However, several state governments, including Delhi and Tamil Nadu , have launched pilot HPV vaccination programs, aiming to cover millions of adolescent girls annually.

Furthermore, India’s domestic vaccine manufacturing capabilities are strengthening. The Department of Biotechnology (DBT) also launched a national mission in 2023 to accelerate vaccine innovation, including those targeting cervical, liver, and lung cancers.

With rising public-private collaboration and increasing foreign investment in biotech hubs , India is emerging as a pivotal market for cancer vaccine development and distribution in the APAC region.

Japan is emerging as a leader in advanced immunotherapy research and regulatory modernization. A key driver is the aging population , which has led to a surge in age-related malignancies such as prostate and colorectal cancer. According to the National Cancer Center Japan , therapeutic cancer vaccines are increasingly being integrated into treatment protocols , especially for late-stage patients who do not respond well to conventional therapies.

Besides, Japan’s regulatory environment is highly conducive to innovation. The Ministry of Health, Labour and Welfare has fast-tracked several cancer vaccines under its Sakigake designation system , allowing quicker approval for breakthrough treatments.

Moreover, academic institutions like Osaka University and Kyoto University are partnering with pharmaceutical firms to advance neoantigen-targeted vaccines, supported by strong intellectual property protections and industry-friendly policies. With growing investment in biotechnology and personalized medicine, Japan plays a crucial role in shaping the future of the APAC Cancer Vaccines Market.

Australia contributes is a notable share of the APAC Cancer Vaccines Market, supported by one of the world’s most successful HPV immunization programs and a strong focus on research-led vaccine development. A key factor driving market growth is the expansion of therapeutic vaccine research , particularly in melanoma and ovarian cancer. According to Peter MacCallum Cancer Centre, several neoantigen-targeted vaccines are undergoing Phase II trials , with promising early results in immune response activation.

Additionally, the Therapeutic Goods Administration (TGA) has introduced accelerated pathways for biologics, encouraging local and international firms to introduce novel cancer vaccines. With strong regulatory frameworks, high healthcare expenditure, and a proactive approach to vaccine innovation, Australia remains a key player in the APAC Cancer Vaccines Market.

South Korea is driven by its strong biotech ecosystem and growing emphasis on personalized cancer immunotherapy.

A major growth area is the development of therapeutic vaccines for gastric, liver, and prostate cancers , which are prevalent in the Korean population.

Additionally, the Korean Centers for Disease Control and Prevention (KCDC) has strengthened its national HPV vaccination program, leading to higher uptake among school-aged girls and boys . As per the National Cancer Center Korea , cervical cancer incidence has declined over the last five years , reflecting the impact of vaccination efforts.

With government-backed R&D initiatives and a growing pipeline of innovative cancer vaccines , South Korea is solidifying its position as a key player in the APAC Cancer Vaccines Market.

KEY MARKET PLAYERS AND COMPETITIVE LANDSCAPE

A few of the noteworthy companies operating in the APAC cancer vaccines market profiled in this report are Dendreon, GlaxoSmithKline, and Merck. In addition, companies with their products in the pipeline are Aduro Biotech, Advantage, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, AVAX Technologies, Bavarian Nordic, Biothera, Celldex Therapeutics, CureVac, Galena Biopharma, Genexine, GlobeImmune, Gradalis, Heat Biologics, Immatics, ImmunoCellular Therapeutics, Inovio Pharmaceuticals, ISA Pharmaceuticals, Juvaris Biotherapeutics, NewLink Genetics, Northwest Biotherapeutics, NovaRx, OncoThyreon, Oncovir, Oxford BioMedica, Prima BioMed, Sotio, Transgene, Ubivac, Vaccinogen, and Vaxon Biotech.

The competition in the APAC Cancer Vaccines Market is shaped by a combination of global pharmaceutical giants and emerging regional biotech firms, all vying to expand their presence in both preventive and therapeutic vaccine segments. Multinational corporations such as Merck & Co. and GSK dominate the preventive vaccine space due to their established product portfolios and extensive distribution networks. These companies have deep-rooted relationships with public health authorities and benefit from long-standing brand recognition and regulatory approvals.

At the same time, local players like Bharat Biotech and Sinovac Biotech are leveraging cost-effective production models and adaptive regulatory strategies to capture market share, especially in lower-income economies. In high-income markets such as Japan and Australia , competition extends beyond traditional vaccines into advanced immunotherapy, where biotech startups and academic institutions are pioneering novel therapeutic approaches using mRNA, DNA, and dendritic cell-based platforms.

The market is also witnessing increased collaboration between private and public sectors, with companies engaging in technology licensing, joint ventures, and co-development agreements to accelerate product pipelines and navigate complex regulatory landscapes. As demand for both preventive and personalized cancer vaccines grows, the competitive environment continues to evolve, driven by innovation, affordability, and strategic market positioning.

Top Players in the Market

One of the leading players in the APAC Cancer Vaccines Market is Merck & Co. , a global pharmaceutical giant known for its HPV vaccine, Gardasil. The company plays a pivotal role in cervical cancer prevention across the region, with strong partnerships in public health programs in India, China, and Southeast Asia. Merck’s commitment to expanding access to preventive oncology vaccines has made it a dominant force in the market.

Another key player is GlaxoSmithKline (GSK) , which contributes significantly through its HPV vaccine, Cervarix. GSK has been actively engaged in government collaborations to improve vaccine coverage in low- and middle-income countries within the APAC region. Its focus on affordability and supply chain innovation has strengthened its position in national immunization programs.

Bharat Biotech is a major regional player driving localized vaccine development and distribution. Based in India, Bharat Biotech is advancing cost-effective HPV vaccines and exploring therapeutic options tailored to the genetic diversity of the APAC population. The company's emphasis on indigenous R&D and scalable manufacturing supports broader access to cancer vaccines across developing markets in the region.

Top Strategies Used by Key Market Participants

A major strategy adopted by key players in the APAC Cancer Vaccines Market is expanding strategic partnerships with governments and public health agencies . Companies are collaborating with national immunization programs to ensure widespread vaccine distribution, particularly in resource-constrained settings where accessibility remains a challenge.

Another critical approach is investing heavily in localized R&D and manufacturing capabilities . By establishing regional research hubs and production facilities, companies can tailor vaccine formulations to regional disease profiles and reduce costs, making cancer vaccines more accessible to diverse populations across the APAC region.

Lastly, leveraging digital health technologies and data analytics for personalized cancer vaccine development is gaining traction. Leading firms are integrating genomics and AI-driven platforms to design customized immunotherapies that target specific tumor antigens, enhancing treatment efficacy and patient outcomes in the evolving landscape of cancer care.

RECENT HAPPENINGS IN THE MARKET

In January 2023, Merck & Co. launched an expanded HPV vaccine outreach initiative in partnership with the Indian government, aiming to increase vaccination coverage in underserved states through mobile clinics and school-based immunization drives.

In August 2023, GSK announced a new manufacturing collaboration with a Vietnamese biotech firm , strengthening its regional supply chain and enabling faster delivery of HPV vaccines to Southeast Asian markets.

In April 2025, Bharat Biotech initiated Phase II trials for its indigenously developed therapeutic cancer vaccine targeting cervical cancer , marking a significant step toward offering affordable, locally produced alternatives in the APAC region.

In October 2023, Kyowa Kirin of Japan entered into a licensing agreement with a South Korean biotech startup to co-develop neoantigen-targeted cancer vaccines, accelerating innovation in personalized oncology treatments.

In June 2025, Moderna expanded its mRNA vaccine research footprint in Singapore , partnering with local universities to develop next-generation cancer vaccines tailored for APAC-specific tumor profiles, reinforcing its foothold in the region.

MARKET SEGMENTATION

This research report on the APAC cancer vaccines market has been segmented and sub-segmented into the following categories

By Cancer Type

• Cervical Cancer Vaccines
• Prostate Cancer Vaccines

By Vaccine Type

• Protein-Based Cancer
• Genetic Cancer Vaccines

By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC